Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Ritonavir
|
| gptkbp:activities |
protease inhibitor
|
| gptkbp:appointed_by |
oral tablet
liquid solution |
| gptkbp:approves |
gptkb:2000
gptkb:FDA |
| gptkbp:brand |
Kaletra
|
| gptkbp:can_be_used_with |
gptkb:Ritonavir
|
| gptkbp:clinical_trial |
gptkb:COVID-19
gptkb:drug combination therapy HIV-1 infection |
| gptkbp:contraindication |
severe liver disease
hypersensitivity to components |
| gptkbp:developed_by |
gptkb:Abb_Vie
|
| gptkbp:dosage_form |
gptkb:tablet
suspension |
| gptkbp:excretion |
urine
feces |
| https://www.w3.org/2000/01/rdf-schema#label |
Lopinavir
|
| gptkbp:indication |
HIV-1 infection
HIV-2 infection |
| gptkbp:ingredients |
C37 H48 N4 O5
|
| gptkbp:interacts_with |
CY P3 A4
CY P2 D6 |
| gptkbp:is_used_for |
gptkb:drug
HIV treatment |
| gptkbp:pharmacokinetics |
highly protein-bound
metabolized by liver |
| gptkbp:provides_information_on |
WHO guidelines
CDC guidelines |
| gptkbp:research_areas |
gptkb:HIV/_AIDS
pharmacogenomics drug interactions viral infections long-term effects clinical efficacy safety profile treatment resistance |
| gptkbp:side_effect |
gptkb:lipodystrophy
fatigue headache nausea abdominal pain diarrhea insulin resistance hyperlipidemia hepatotoxicity pancreatitis |
| gptkbp:storage |
room temperature
protected from light |
| gptkbp:type_of |
192725-17-0
|
| gptkbp:weight |
628.88 g/mol
|